Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SHBG | P04278 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.36 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.33 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | UGT2B7 | P16662 | 2/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14443275 | 1.00 | TP53 (0.41) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL14443274 | 1.00 | TP53 (0.41) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL16230728 | 0.97 | TP53 (0.37) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL10104528 | 0.97 | TP53 (0.37) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL16230660 | 0.97 | TP53 (0.37) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL16805015 | 0.92 | UGT2B7 (0.33) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL3416717 | 0.86 | — | — | |
| SCHEMBL11911962 | 0.86 | — | — | |
| SCHEMBL9221102 | 0.82 | TP53 (0.39) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL28922673 | 0.78 | TP53 (0.37) | TP53KDM4EGMNNLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170112785-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2017-04-27 | — | — | US | disclosed |
| US-8946231-B2 | P2X3, receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010111059-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20090198024-A1 | FORMALDEHYDE-FREE, CARBONYL- AND RING-HYDROGENATED KETONE-ALDEHYDE RESINS BASED ON ALKYL ARYL KETONES AND FORMALDEHYDE WHICH HAVE A LOW OH FUNCTIONALITY AND A PROCESS FOR PREPARING THEM | EVONIK DEGUSSA GMBH (DE) | 2009-08-06 | — | — | US | disclosed |
| US-20090099332-A1 | FORMALDEHYDE-FREE, OH-FUNCTIONAL, CARBONYL- AND RING-HYDROGENATED KETONE-ALDEHYDE RESINS BASED ON ALKYL ARYL KETONES AND FORMALDEHYDE AND A PROCESS FOR PREPARING THEM | EVONIK DEGUSSA GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| EP-0514332-B1 | Bis-phosphites | CIBA GEIGY AG (CH) | 1996-04-17 | — | — | EP | disclosed |
| US-5308902-A | Heterocyclic fused ring structures, stabilizers for PVC and polyolefins | CIBA-GEIGY CORPORATION (US) | 1994-05-03 | — | — | US | disclosed |
| EP-0514332-A1 | Bis-phosphites | CIBA-GEIGY AG (CH) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | TP53 4666/4885KDM4E 3919/4885GMNN 4597/4885 |
| US-20170112785-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | TP53 894/4885KDM4E 2099/4885GMNN 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.